LXRX Lexicon Pharmaceuticals PE ratio, current and historical analysis
The current price-to-earnings ratio of LXRX can't be determined, as the TTM EPS of -$0.75 is negative. The most recent PE ratio recorded for Lexicon Pharmaceuticals was 9.98 in June 2021.
LXRX PE ratio history
Over the last six years, the average PE ratio of Lexicon Pharmaceuticals has been 4.63. In the past six years, LXRX's PE ratio was at its highest in the Jun 2021 quarter at 9.98, with a price of $4.59 and an EPS of $0.46. The Sep 2019 quarter recorded the bottom point at 1.95, with a price of $3.01 and an EPS of $1.54.
Lexicon Pharmaceuticals PE ratio by year
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | N/A | N/A |
| 2021 | N/A | N/A |
| 2020 | N/A | N/A |
| 2019 | 3.37 | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
LXRX average PE ratio chart
LXRX PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| REGN Regeneron Pharmaceuticals Inc | 17.22 | $81.81B |
| TMO Thermo Fisher Scientific Inc | 32.28 | $197.41B |
| BMRN Biomarin Pharmaceutical Inc | 37.32 | $12.09B |
| LGND Ligand Pharmaceuticals Inc | 44.15 | $2.2B |
| RARE Ultragenyx Pharmaceutical Inc | N/A | $4.25B |
| ILMN Illumina Inc | N/A | $21.73B |
| ESPR Esperion Therapeutics Inc | N/A | $486.68M |
| LXRX Lexicon Pharmaceuticals Inc | N/A | $278.96M |
Frequently asked questions
What is Lexicon Pharmaceuticals's PE ratio?
The current price to earnings ratio of LXRX can't be calculated, as its EPS of -$0.75 is negative.
What is the highest PE ratio for LXRX?
The highest quarterly PE ratio in the last six years has been 9.98 and it was in the Jun 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.